Science1 distinct publisher2 min readPublished
Ohio State reports that glioblastoma suppresses the enzyme PP2A using three of its own proteins, and that knocking those down in lab and animal models killed more cells and left the survivors easier to irradiate. No patients have been treated.
The Scientist · Science desk
Compiled by The ScientistSomething wrong?How this is made
PP2A regulates the signals a cell uses to grow, survive and recover from treatment damage [4], and the paper's own title states the claim plainly: the cell's endogenous PP2A inhibitors switch on oncogenic and DNA damage response kinases [19]. DNA damage response is the machinery a tumour uses to survive being irradiated. Take the brake off those kinases and you would expect a radioresistant cell; put the brake back and you would expect a more radiosensitive one. That is a coherent reason for the sensitisation the group reports after blocking ANP32A, CIP2A and SET in laboratory and animal models [6][5].
The release does not say how big any of this effect is. "Fewer cancer cells survived" arrives without a denominator, and there are no effect sizes, animal counts, radiation doses or survival curves in the summary [17]. Those numbers exist in the journal article; they are not what most readers will meet.
The strongest sentence in the release also raises a design question. Suppressing SET prevented tumours from developing [7], and the release does not say whether SET was suppressed before or after tumours were established [18]. Preventing a tumour from forming and shrinking one that already exists are different experiments, and only the second describes the situation of a person with a glioblastoma diagnosis.
Timing is worth noting for anyone tracking how fast this field moves from print to public. The study ran in the May 2026 issue of Cancer Letters [13]; Ohio State issued its summary on September 6 [15], roughly four months later [16].
SET's position at the top of the list is a within-study ranking against two other PP2A inhibitors in one group's hands [8], and the summary does not give the measurement that ranking rests on [17]. Arnab Chakravarti, who chairs radiation oncology at the OSUCCC - James, frames the finding as a path to test whether restoring PP2A makes radiation and chemotherapy work better [9], which is the right verb: test. The mechanism is plausible and the target is worth the next grant. For now, bedside practice should stay unchanged [10].
Ranked by verification strength, evidence, and original report placement.
Researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute identified a protein called SET as a possible target that could make glioblastoma cells easier to kill with existing therapies.
Rather than replacing current treatments, the strategy is designed to help existing treatments work better.
Glioblastoma is among the most lethal forms of cancer, and treatment options have changed relatively little because the tumours frequently withstand both radiation and chemotherapy.
PP2A is an enzyme involved in regulating signals that cancer cells use to grow, survive, and recover from treatment-related damage.
Glioblastoma cells appear to interfere with PP2A using three proteins called ANP32A, CIP2A and SET.
When the researchers blocked ANP32A, CIP2A and SET in laboratory and animal models, fewer cancer cells survived, and the remaining cells became more vulnerable to radiation.
Distinct publishers with included, body-backed reporting in this cluster.
1 article · September 5, 2026
Follow any of these and your For You feed starts watching them — no settings page required.
science
Hollings researchers turn chemoresistance into a target by blocking LOX first1 distinct publisher
science
Injured mouse axons regrew after researchers switched off a toxin-sensing protein1 distinct publisher
product
Half of severe alopecia patients on upadacitinib hit 80% scalp coverage by week 241 distinct publisher
science
Ten years of hip scans place coffee's bone-density signal above five cups a day1 distinct publisher
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Real paper, unquantified retelling
A peer-reviewed article exists and is fully cited, down to Cancer Letters volume 645, article 218325 and its DOI. What reaches the reader about it is Ohio State's own prose: 'fewer cancer cells survived', tumours 'prevented' from developing. No model system, dose, sample size or survival figure appears. Verifying that the work happened is easier here than learning what it showed.
Cell culture and animals only
Nothing has been used on a patient. Ohio State says the results are preliminary and untested in humans, and the one existing drug mentioned as a PP2A activator comes with an instruction not to take it for glioblastoma outside a trial. There is no prescribing, enrolment or licensing activity to count.
Headline runs ahead of its own text
'Scientists find a weak spot in one of the deadliest brain cancers' sits above a release that calls the results preliminary, says no patient has been treated, and warns readers off the antipsychotic. The overstatement lives almost entirely in the framing; the body does the caveating that institutional summaries usually skip. The gap would mostly close if the numbers ran alongside the language.
The subject is also the narrator
Ohio State's medical centre wrote this about Ohio State's cancer centre, with NIH, NCI and its own institutional grants named as support and the department chair supplying both quotes. ScienceDaily passes the text through as provided. That is the ordinary economics of academic press distribution rather than anything concealed, but the enthusiasm and the restraint both come from the party whose next grant depends on the work.
Sure of the wording, blind to the numbers
What Ohio State said and when is settled: a September 6 summary of a paper that ran four months earlier in the May issue, with authors and DOI attached. What the experiments measured is not available at this remove, and with a single publisher relaying a single release there is no second reading to lean on.